Aurinia Pharmaceuticals Inc. Quarterly Operating Income (Loss) in USD from Q1 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Aurinia Pharmaceuticals Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2019 to Q2 2024.
  • Aurinia Pharmaceuticals Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$1.51M, a 90.6% increase year-over-year.
  • Aurinia Pharmaceuticals Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$60.7M, a 27.2% increase year-over-year.
  • Aurinia Pharmaceuticals Inc. annual Operating Income (Loss) for 2023 was -$91.7M, a 17.7% increase from 2022.
  • Aurinia Pharmaceuticals Inc. annual Operating Income (Loss) for 2022 was -$111M, a 38.3% increase from 2021.
  • Aurinia Pharmaceuticals Inc. annual Operating Income (Loss) for 2021 was -$181M, a 73.3% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$60.7M -$1.51M +$14.7M +90.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 -$75.4M -$13.3M +$16.3M +55.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 -$91.7M -$29.7M -$1.57M -5.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-15
Q3 2023 -$90.1M -$16.3M -$6.76M -71.2% Jul 1, 2023 Sep 30, 2023 10-K 2024-02-15
Q2 2023 -$83.4M -$16.2M +$19.8M +55.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 -$103M -$29.6M +$8.3M +21.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 -$111M -$28.1M +$4.61M +14.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-15
Q3 2022 -$116M -$9.5M +$40.9M +81.1% Jul 1, 2022 Sep 30, 2022 10-K 2024-02-15
Q2 2022 -$157M -$36M +$11.1M +23.6% Apr 1, 2022 Jun 30, 2022 10-K 2024-02-15
Q1 2022 -$168M -$37.9M +$12.7M +25.1% Jan 1, 2022 Mar 31, 2022 10-K 2024-02-15
Q4 2021 -$181M -$32.7M -$24.7M -306% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-28
Q3 2021 -$156M -$50.4M -$8.04M -19% Jul 1, 2021 Sep 30, 2021 10-K 2023-02-28
Q2 2021 -$148M -$47.1M -$20.3M -75.5% Apr 1, 2021 Jun 30, 2021 10-K 2023-02-28
Q1 2021 -$128M -$50.5M -$23.5M -86.8% Jan 1, 2021 Mar 31, 2021 10-K 2023-02-28
Q4 2020 -$104M -$8.05M +$26.8M +76.9% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-28
Q3 2020 -$131M -$42.3M -$18.2M -75.8% Jul 1, 2020 Sep 30, 2020 10-K 2022-02-28
Q2 2020 -$113M -$26.9M -$9.72M -56.7% Apr 1, 2020 Jun 30, 2020 10-K 2022-02-28
Q1 2020 -$103M -$27.1M -$12.2M -81.7% Jan 1, 2020 Mar 31, 2020 10-K 2022-02-28
Q4 2019 -$90.9M -$34.8M Oct 1, 2019 Dec 31, 2019 10-K 2021-02-24
Q3 2019 -$24.1M Jul 1, 2019 Sep 30, 2019 10-K 2021-02-24
Q2 2019 -$17.1M Apr 1, 2019 Jun 30, 2019 10-K 2021-02-24
Q1 2019 -$14.9M Jan 1, 2019 Mar 31, 2019 10-K 2021-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.